vTv Therapeutics
VTVT
35 hedge funds and large institutions have $24.4M invested in vTv Therapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 7 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
1% more capital invested
Capital invested by funds: $24.1M → $24.4M (+$304K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 41 → 35 (-6)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$245K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$136K |
| 3 |
State Street
Boston,
Massachusetts
|
+$132K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$123K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.48M |
| 2 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$1.01M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$507K |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$353K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$119K |
VTVT Hedge Fund Activity: Q2 2016 in Review
35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2016, worth a combined $24.4M — up 1.3% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VTVT and 1 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 15 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $245K. The largest seller was Millennium Management, exiting entirely with an estimated $1.48M sold.
- 35 institutional investors held vTv Therapeutics (VTVT) as of Q2 2016, down from 41 in Q1 2016.
- Funds reported $24.4M of vTv Therapeutics stock for Q2 2016, up 1.3% quarter-over-quarter.
- 1 fund opened new vTv Therapeutics positions in Q2 2016 and 7 closed out, a net change of -6 holders.
- The largest vTv Therapeutics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $245K added.
- The largest vTv Therapeutics seller in Q2 2016 was Millennium Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2016.